Update shared on27 Aug 2025
Fair value Increased 1.27%The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43.
What's in the News
- FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
- Viatris reaffirmed 2025 revenue guidance, expecting total revenues between $13.5 billion and $14 billion, projecting results in the top half of the range.
- Viatris completed the repurchase of 79.3 million shares (6.62% of shares outstanding) for $849.96 million under its buyback program.
- The Phase 3 study of pimecrolimus 0.3% (MR-139) ophthalmic ointment for blepharitis failed its primary endpoint, but the company reported positive results from Phase 3 trials of MR-142 for night driving impairment and MR-141 for presbyopia.
- Viatris was added to the Russell 2500 Index and Russell 2500 Value Index.
Valuation Changes
Summary of Valuation Changes for Viatris
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $11.29 to $11.43.
- The Consensus Revenue Growth forecasts for Viatris has risen from 0.8% per annum to 0.9% per annum.
- The Future P/E for Viatris remained effectively unchanged, moving only marginally from 35.92x to 36.36x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.